Related references
Note: Only part of the references are listed.A novel MCT1 and MCT4 dual inhibitor reduces mitochondrial metabolism and inhibits tumour growth of feline oral squamous cell carcinoma
Ali Khammanivong et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2020)
The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study
Letizia Porcelli et al.
SCIENTIFIC REPORTS (2020)
R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma
Jeroen Overman et al.
ELIFE (2019)
The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer
Alexa Montoya et al.
BIOMEDICAL JOURNAL (2019)
Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma
Kate Megquier et al.
MOLECULAR CANCER RESEARCH (2019)
Propranolol exhibits activity against hemangiomas independent of beta blockade
Maiko Sasaki et al.
NPJ PRECISION ONCOLOGY (2019)
Large nose angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol
J. Daguze et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Fatty acid synthase as a potential therapeutic target in feline oral squamous cell carcinoma
J. Z. Walz et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2018)
Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma
Xinwei Kuang et al.
ONCOTARGET (2018)
Emerging roles and regulation of MiT/TFE transcriptional factors
Min Yang et al.
CELL COMMUNICATION AND SIGNALING (2018)
Current and Future Directions for Angiosarcoma Therapy
Vaia Florou et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
The transcription factors TFE3 and TFEB amplify p53 dependent transcriptional programs in response to DNA damage
Eutteum Jeong et al.
ELIFE (2018)
Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer
Alexa Montoya et al.
ONCOTARGET (2017)
Effect of lysosomotropic molecules on cellular homeostasis
Omer F. Kuzu et al.
PHARMACOLOGICAL RESEARCH (2017)
Lysosomal adaptation: How cells respond to lysosomotropic compounds
Shuyan Lu et al.
PLOS ONE (2017)
Lysosomes as mediators of drug resistance in cancer
Benny Zhitomirsky et al.
DRUG RESISTANCE UPDATES (2016)
Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review
Christine Leaute-Labreze et al.
PEDIATRICS (2016)
Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study
Eddy Pasquier et al.
EBIOMEDICINE (2016)
Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma
Heather L. Gardner et al.
BMC VETERINARY RESEARCH (2015)
Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012)
Kristin M. Wendelburg et al.
JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION (2015)
A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma
C. Leaute-Labreze et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma
Sandra P. D'Angelo et al.
ONCOLOGY (2015)
Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade
William Chow et al.
JAMA DERMATOLOGY (2015)
Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment
Eddy Pasquier et al.
Oncotarget (2015)
Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance
Benny Zhitomirsky et al.
ONCOTARGET (2015)
Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma
Shripad Banavali et al.
ECANCERMEDICALSCIENCE (2015)
Time-Dependent Effects of Hydrophobic Amine-Containing Drugs on Lysosome Structure and Biogenesis in Cultured Human Fibroblasts
Randall Logan et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
SMURF1 silencing diminishes a CD44-high cancer stem cell-like population in head and neck squamous cell carcinoma
Ali Khammanivong et al.
MOLECULAR CANCER (2014)
Lysosomal drug sequestration as a mechanism of drug resistance in vascular sarcoma cells marked by high CSF-1R expression
Brandi H. Gorden et al.
VASCULAR CELL (2014)
β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
E. Pasquier et al.
BRITISH JOURNAL OF CANCER (2013)
A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis
M. Kracikova et al.
CELL DEATH AND DIFFERENTIATION (2013)
Physico chemical characterization of a novel anti-cancer agent and its comparison to Taxol®
Amit K. Shah et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2013)
Pathogenesis of human hemangiosarcomas and hemangiomas
Liping Liu et al.
HUMAN PATHOLOGY (2013)
Targeting of Beta Adrenergic Receptors Results in Therapeutic Efficacy against Models of Hemangioendothelioma and Angiosarcoma
Jessica M. Stiles et al.
PLOS ONE (2013)
Lysosomal Sequestration (Trapping) of Lipophilic Amine (Cationic Amphiphilic) Drugs in Immortalized Human Hepatocytes (Fa2N-4 Cells)
Faraz Kazmi et al.
DRUG METABOLISM AND DISPOSITION (2013)
Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas
Antoine Italiano et al.
CANCER (2012)
Mitochondrial metabolism in cancer metastasis Visualizing tumor cell mitochondria and the reverse Warburg effect in positive lymph node tissue
Federica Sotgia et al.
CELL CYCLE (2012)
Cationic Amphiphilic Drugs Cause a Marked Expansion of Apparent Lysosomal Volume: Implications for an Intracellular Distribution-Based Drug Interaction
Ryan S. Funk et al.
MOLECULAR PHARMACEUTICS (2012)
Angiosarcoma: State of the art and perspectives
Nicolas Penel et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Angiosarcoma Clinical and Molecular Insights
Guy Lahat et al.
ANNALS OF SURGERY (2010)
Lymphocyte Infiltration, Expression of Interleukin (IL)-1, IL-6 and Expression of Mutated Breast Cancer Susceptibility Gene-1 Correlate with Malignancy of Canine Mammary Tumours
J. -H. Kim et al.
JOURNAL OF COMPARATIVE PATHOLOGY (2010)
ABCG2-mediated dyecycle violet efflux defined side population in benign and malignant prostate
Grinu Mathew et al.
CELL CYCLE (2009)
Gene Expression Profiles of Sporadic Canine Hemangiosarcoma Are Uniquely Associated with Breed
Beth A. Tamburini et al.
PLOS ONE (2009)
Identification of side population cells from bladder cancer cells by dyecycle violet staining
Jun Jun She et al.
CANCER BIOLOGY & THERAPY (2008)
Propranolol for severe hemangiomas of infancy
Christine Leaute-Labreze et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
ABC multidrug transporters: structure, function and role in chemoresistance
Frances J. Sharom
PHARMACOGENOMICS (2008)
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site:: a retrospective study of 161 cases
J. Fayette et al.
ANNALS OF ONCOLOGY (2007)
Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes
Mikael Herlevsen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Treatment and outcome of 82 patients with angiosarcoma
John A. Abraham et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine
Line Groth-Pedersen et al.
CANCER RESEARCH (2007)
Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation
Angela R. Lamerato-Kozicki et al.
EXPERIMENTAL HEMATOLOGY (2006)
Characterization of β-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein
I Bachmakov et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2006)
The dog as a cancer model
Chand Khanna et al.
NATURE BIOTECHNOLOGY (2006)
A 14-year retrospective review of angiosarcoma: Clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy
MG Fury et al.
CANCER JOURNAL (2005)
Intracellular drug sequestration events associated with the emergence of multidrug resistance: A mechanistic review
M Duvvuri et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2005)
The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors
JG Baker
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium
SP Fosmire et al.
LABORATORY INVESTIGATION (2004)
Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model
N Akhtar et al.
NEOPLASIA (2004)
Cutaneous angiosarcoma of the scalp - A multidisciplinary approach
TM Pawlik et al.
CANCER (2003)
SVR angiosarcomas can be rejected by CD4 costimulation dependent and CD8 costimulation independent pathways
JL Arbiser et al.
MOLECULAR MEDICINE (2002)
Modulation of P-glycoprotein activity in Calu-3 cells using steroids and β-ligands
KO Hamilton et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2001)
Share Paper
